Haplogen GmbH is screening haploid human cells to identify new host factors required for bacterial or viral infection, which it hopes will lead to the development of anti-infectives with less potential for resistance.

Haplogen was founded to commercialize a screening system developed in the lab of one of the company's scientific founders, Thijn Brummelkamp, at the Whitehead Institute for Biomedical Research.